Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury

Table 1 Dose and developmental stage-dependent actions of TFBP on chicken embryos

TFBP topically was applied to early (E2.5) and mid (E4) developmental stage chicken embryos at several doses. Embryos were observed 24 h later and at every 24 h up to the end of the experiment at 72 h. Death rates increased as the dose of TFBP increased, likely due to drug-induced toxicity. At TFBP 3.5 and 7.0 μM doses, no effects on embryo development were seen; the deaths observed appeared to be due to damage of the embryonic membranes that were removed before application of the drugs, as the embryos themselves appeared normal. With the 14.0 μM dose, one embryo had micro-opthalmia of the eye (*), in the eye facing away from the site of drug application, but no other developmental anomalies (and was alive at the end of the experiment). The micro-opthalmia could thus potentially be a spontaneous malformation, as the 3 deaths seen at the 14 μM dose occurred quite late in development (around 48 and 72 h after drug application) and those embryos appeared developmentally and morphologically normal. All control embryos (DMSO; N = 2) were normal

ISSN: 1423-0127